摘要
目的:观察长春瑞滨联合顺铂方案治疗蒽环类及紫杉类耐药转移性乳腺癌的疗效和不良反应。方法:长春瑞滨联合顺铂方案治疗蒽环类及紫杉类耐药转移性乳腺癌38例。长春瑞滨25mg/m2静脉滴注,第1、8天,顺铂70mg/m2分4次静脉滴注,第1-4天。21天为1个周期,至少应用2个周期。结果:本组患者治疗有效率36.8%(14/38),中位生存时间15.6(95%CI12.8-17.2)个月,中位疾病进展时间6.2个月,1年生存率68.4%。无化疗相关死亡,主要不良反应为骨髓抑制及胃肠道反应。结论:长春瑞滨联合顺铂方案对蒽环类及紫杉类耐药的转移性乳腺癌有较好的近期疗效,不良反应可耐受,为有效的解救方案。
Objective:To observe the efficacy and adverse effects of NVB and DDP for metastatic breast cancer resistant to anthracycline and taxane. Methods: Thirty eight patients with metastatic breast cancer resistant to anthracycline and taxane were be treated with NVB and DDP. NVB 25mg/m^2 iv d1,t DDP 70mg/m^2iv d1-4once daily, 21 days as one cycle. All patients completed chemotherapy at least 2 cycles. Results: The overall response rate was 36.8% (14/38) ,median survival time was 15.6 months, 1 year survival rate was 68.4%. There was no death case associated with chemotherapy. The main taxicity was myelosuppression and gastrointestinal reaction. Conclu- sion: The combined chemotherapy with NVB and DDP is effective in short term and tolerable regimen for metastatic breast cancer resistant to anthracyeline and taxane.
出处
《现代肿瘤医学》
CAS
2010年第6期1134-1136,共3页
Journal of Modern Oncology
关键词
乳腺肿瘤
转移
长春瑞滨
顺铂
疗效
不良反应
breast neoplasms
metastasis
vinorelbine
cisplatin
efficacy
toxicity